Find and Pitch Jounalists, Get Your Story Covered

Tags: statins statin lipid statin therapy kidney disease

	Profile	Recent Articles on Subject
1	Kristen Monaco MedPage Today	SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease - 18 days ago
2	Theresa Gaffney STAT News Audio producer, health reporter. Boston audio productionhealth reporting	Salt substitutes as a way to lower risk of death, stroke - 26 days ago
3	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 3 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 9 months ago STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug - over 1 year ago STAT+: After decades in use, heart stents finally beat placebo. It took a bold researcher - over 1 year ago
4	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 3 months ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 8 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 8 months ago STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 9 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 10 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - over 1 year ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness - 3 months ago STAT+: A second Roche obesity drug shows promise in early studies - 8 months ago STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - about 1 year ago STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial - over 1 year ago STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial - over 1 year ago
7	David Nield Science Alert Freelance tech, science writer. Marple, Manchester, UK Technologysciencewriting	Common Heart Meds May Sharply Reduce Dementia Risk, Study Says - 3 months ago A Game-Changing Vaccine Could Lower 'Bad' Cholesterol by 30% - about 1 year ago
8	Nicole Lou MedPage Today Medical reporter @medpagetoday. Bird advocate. undisclosed remote location medical reporting	More Lp(a)-Reducing Tx; Cardiac Denervation for Afib; LAA Occluders at 5 Years - 3 months ago First DCB Approved; DAPT Bleeds With Low LDL-C; Pre-CABG Cardiac Rehab - 12 months ago Statins and CKD; Farxiga's Limited Symptom Improvement; Stop Wasted TNKase - about 1 year ago Alleged Stroke Trial Misconduct; Ultrasound Tx for Severe AS; Farxiga's eGFR Drops - over 1 year ago Statins Reach More Patients With Pharmacist's Orders - over 1 year ago Novel PCSK9 Inhibitor Recaticimab Lowers Lipids With Less Frequent Shots - over 1 year ago Drug-Coated Balloon Answers 'Embarrassing' Need for In-Stent Restenosis in U.S. - over 1 year ago Highly Potent Statin Stands Out for Diabetes, Cataract Risks - over 1 year ago FXI Inhibitor Cuts Bleeds in Afib; COAPT Extends to Real World; AI Stroke Triage - over 1 year ago
9	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 4 months ago STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 10 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 10 months ago STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills - 11 months ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 11 months ago STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label - 12 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds - about 1 year ago STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial - over 1 year ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - over 1 year ago STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial - over 1 year ago
10	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more - 5 months ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 12 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 12 months ago STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study - about 1 year ago STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients - over 1 year ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - over 1 year ago

Journalists covering statin